bufalin has been researched along with Multiple Myeloma in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Cao, Y; Ding, P; Duan, J; Gu, C; Guo, M; Li, N; Qiao, L; Shao, M; Sun, S; Tang, C; Tang, X; Wang, Y; Wei, R; Xiao, Y; Yang, Y; Zhang, L; Zhou, Y | 1 |
| Cao, Y; Li, JM; Tong, J; Wang, Y; Wu, YL; Xiang, RF; Xu, WB; Yan, H; Zhang, N | 1 |
| Cao, Y; Chen, YB; Huang, H; Liu, W; Lu, SY; Wang, Y; Wei, W; Wu, YL; Yan, H | 1 |
3 other study(ies) available for bufalin and Multiple Myeloma
| Article | Year |
|---|---|
AHSA1 is a promising therapeutic target for cellular proliferation and proteasome inhibitor resistance in multiple myeloma.
Topics: Animals; Antineoplastic Agents; Bufanolides; Cell Proliferation; Disease Models, Animal; Gene Expression Profiling; Humans; Mice; Mice, Inbred NOD; Molecular Chaperones; Multiple Myeloma; Proteasome Inhibitors; Transfection | 2022 |
MK2206 enhances the cytocidal effects of bufalin in multiple myeloma by inhibiting the AKT/mTOR pathway.
Topics: Animals; Bufanolides; Cell Line, Tumor; Drug Synergism; Female; Heterocyclic Compounds, 3-Ring; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Mice, SCID; Multiple Myeloma; Proto-Oncogene Proteins c-akt; Signal Transduction; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays | 2017 |
Targeting poly (ADP-ribose) polymerase partially contributes to bufalin-induced cell death in multiple myeloma cells.
Topics: Bufanolides; Cell Cycle Checkpoints; Cell Death; Cell Line, Tumor; Cell Proliferation; Drug Screening Assays, Antitumor; Enzyme Activation; Humans; Molecular Targeted Therapy; Multiple Myeloma; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases | 2013 |